跳至主要内容
临床试验/JPRN-jRCTs031200073
JPRN-jRCTs031200073
已完成
1 期

The efficacy of anti-IL-4/13 receptor monoclonal antibody on chronic prurigo

Tsuyoshi Namiki0 个研究点目标入组 2 人2020年7月21日

概览

阶段
1 期
干预措施
未指定
疾病 / 适应症
chronic prurigo
发起方
Tsuyoshi Namiki
入组人数
2
状态
已完成
最后更新
2年前

概览

简要总结

In this study, two cases were successfully treated with dupilumab. Further research is needed to validate the effectiveness of dupilumab in the treatment of prurigo chronica multiformis.

注册库
who.int
开始日期
2020年7月21日
结束日期
2022年7月25日
最后更新
2年前
研究类型
Interventional
性别
All

研究者

发起方
Tsuyoshi Namiki

入排标准

入选标准

  • 1\) a patient with chronic prurigo
  • 2\) a patient who was not improved by oral anti\-histamine drug and topical steroid
  • 3\) a patient at age 20 or over
  • 4\) a patient who fully understand and agree to join this clinical study
  • 5\) outpatient

排除标准

  • 1\) a patient orally administrated immune suppressants or high\-dose steroid within three months
  • 2\) a patient who undergo UV photo therapy
  • 3\) a patinet who was treated with anti\-IgE antibody within four months
  • 4\) a patient suffering from severe visceral diseases, autoimmune diseases, blood dosorders, and mental disorders
  • 5\) a patient who is pregnant or breast\-feed
  • 6\) a patinet who is infected with parasite
  • 7\) a patient who is sensitive to this medication
  • 6\) a patient judged inadequate to this study

结局指标

主要结局

未指定

相似试验